Old Web
English
Sign In
Acemap
>
authorDetail
>
Jose A. Figueroa
Jose A. Figueroa
Cancer research
Medicine
Pharmacokinetics
Immunology
Exatecan
3
Papers
108
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer
2004
Clinical Cancer Research
Miguel A. Villalona-Calero
Paul S. Ritch
Jose A. Figueroa
Gregory A. Otterson
Robert Belt
Edward Dow
Sebastian George
James M. Leonardo
Spence McCachren
G. Lance Miller
Manuel R. Modiano
Manuel Valdivieso
Richard S. Geary
Jennifer W. Oliver
Jon T. Holmlund
Show All
Source
Cite
Save
Citations (68)
A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies
2003
Clinical Cancer Research
Mitchell Garrison
Lisa A. Hammond
Charles E. Geyer
Garry Schwartz
Anthony W. Tolcher
Leslie Smetzer
Jose A. Figueroa
M. P. Ducharme
John Coyle
Chris H. Takimoto
Robert De Jager
Eric K. Rowinsky
Show All
Source
Cite
Save
Citations (13)
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (‘Iressa’), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in advanced colorectal cancer (ACRC)
2001
European Journal of Cancer
Lisa A. Hammond
Jose A. Figueroa
L. Schwartzberg
Leonel Ochoa
Manuel Hidalgo
N. Olivo
Garry Schwartz
Lon Smith
J. Ochs
E. K. Rowinsky
Show All
Source
Cite
Save
Citations (27)
1